Drugs / SSS11
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03388515 | Oct 2017 → Jul 2019 | gout | Shenyang Sunshine Pharmaceutical Co., LTD. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SSS11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03388515 ↗ |
| Known as | pegsiticase | “SSS11 is pegsiticase consisting of a recombinant uricase conjugated to multiple 20kDa PEG molecules.” NCT03388515 ↗ |
| Modality | Protein / enzyme biologic | “a recombinant uricase” NCT03388515 ↗ |
| Route | Intravenous | “IV infusion for 60 min.” NCT03388515 ↗ |